Overview

Despite ongoing vaccination efforts, PEDV continues to challenge swine producers with outbreaks that compromise piglet survival and herd productivity. Existing live attenuated vaccines, while immunogenic, are constrained by recombination and reversion risks, limiting their safety and reliability. This new technology directly addresses these critical limitations by providing a genetically stable, recombination-resistant live attenuated vaccine for PEDV.

The Opportunity

This vaccine platform sets a new standard for swine health by combining advanced genetic engineering with proven live attenuated vaccine benefits. Its design enables reliable, long-term protection with reduced risk of side effects, supporting both biosecurity and operational efficiency in commercial swine production. By minimizing the need for repeated interventions and lowering outbreak-related losses, it offers producers a sustainable tool for managing PEDV and related viral threats. Preliminary validation in piglets demonstrates 100% survivorship following immunization.

Key Advantages

• Regulatory Readiness: Built on a robust, genetically stable platform with strong preclinical data, accelerating path to market.
• High Titer Production: Engineered for efficient propagation in cell culture, supporting scalable manufacturing.
• Operational Simplicity: Designed for convenient administration, fitting seamlessly into existing swine health protocols.
• Broad-Spectrum Potential: Demonstrated capacity for cross-protective immunity across diverse PEDV genotypes.
• Platform Versatility: Adaptable for rapid development against emerging coronavirus strains and other nidoviruses in animal health.

Help Transform Swine Health Management

By adopting this advanced vaccine technology, swine producers can safeguard their herds from devastating PEDV outbreaks, reduce veterinary costs, and achieve more predictable production outcomes. The vaccine’s design not only addresses current industry challenges but also positions operations for future growth and resilience in a rapidly evolving animal health landscape.

Contact us to explore licensing opportunities and advance swine health with this next-generation vaccine solution.